Difference between revisions of "Buserelin (Suprefact)"
Jump to navigation
Jump to search
m |
m |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *1984-08-16: EURD |
| + | |||
==Also known as== | ==Also known as== | ||
*'''Code names:''' HOE-766, ICI-123215, S74-6766 | *'''Code names:''' HOE-766, ICI-123215, S74-6766 | ||
| Line 14: | Line 15: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
[[Category:Nasal medications]] | [[Category:Nasal medications]] | ||
| + | |||
| + | [[Category:GnRH analogs]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
Latest revision as of 11:51, 23 September 2023
Mechanism of action
Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis.
Diseases for which it is used
History of changes in EMA indication
- 1984-08-16: EURD
Also known as
- Code names: HOE-766, ICI-123215, S74-6766
- Brand names: Bigonist, Etilamide, Profact, Receptal, Suprecur, Suprefact